Marc Duey Acquires 30,000 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey bought 30,000 shares of Aprea Therapeutics stock in a transaction dated Wednesday, October 16th. The shares were purchased at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the transaction, the director now owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Marc Duey also recently made the following trade(s):

• On Monday, October 14th, Marc Duey acquired 190 shares of Aprea Therapeutics stock. The stock was purchased at an average price of $2.58 per share, for a total transaction of $490.20.

Aprea Therapeutics Stock Performance

Shares of Aprea Therapeutics stock traded up $0.25 during trading on Thursday, reaching $3.75. The company had a trading volume of 25,484 shares, compared to its average volume of 19,916. The company has a market cap of $20.36 million, a price-to-earnings ratio of -1.13 and a beta of 1.03. Aprea Therapeutics, Inc. has a fifty-two week low of $2.15 and a fifty-two week high of $8.85. The firm’s fifty day moving average is $3.16 and its 200-day moving average is $4.19.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Monday, August 12th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. On average, research analysts anticipate that Aprea Therapeutics, Inc. will post -2.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

APRE has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Monday, August 12th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.